anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE:To enable assay of a bodily liquor component simply and at a high accuracy, by performing a second antigen reaction to make unreacted antibody left in the first antigen-antibody reaction react with a label antigen. CONSTITUTION:An antibody 2 is attached to a carrier 1 to form a regent 6. The reagent 6 thus obtained is added to a sample body liquor to perform a first antigen reaction between the reagent and an antigen with an unknown concentration contained in the sample body liquor. After the reaction, a labelled antigen 3 coupled to a fluorescent pigment 4 is added to a reaction liquid to cause a second antibody reaction with the unreacted antibody. After the reaction, the intensity of fluorescence, forward scattered light and side scattered light in the reaction liquid is measured to determined the integrated value of the intensity of fluorescence from the intensity measured to obtain the amount of reaction with the antigen 3 from the integrated value. Then, an second antigen reaction is caused using the same antigen 3 to determine a reference amount of reaction with which the amount of reaction previously determined is compared to obtain the concentration of the antigen in the sample bodily liquor. The concentration of the antibody can be determined by replacing the antigen with the antibody in the measuring method as mentioned above.
PROBLEM TO BE SOLVED: To provide the subject cosmetic high in emollient feeling, hardly providing powdery feeling, capable of being lightly spread on the skin, good in finishing feeling and excellent in melt repletion by formulating phosphorus acid-based surface active agent and a specific platy powder. SOLUTION: This cosmetic includes (A) 0.01-3 wt.% phosphoric acid-based surfactant (preferably, lecithin or polyoxyethylene-addition alkylether phosphate, etc.), and (B) 5-40 wt.% platy powder having 1-400 μm average particle diameter (preferably a platy clay mineral, a luminescence pigment and ultraviolet-shielding powder). Preferably, the cosmetic further includes (C) 1-30 wt.% spherical powder having 3 50 μm average particle diameter (for example, a nylon powder and silica). The make-up cosmetics such as a lipstick, a foundation, and an eye shadow are cited as the cosmetic capable of readily manifesting the effect as the cosmetic. As the result, the objective cosmetic excellent in persistence of makeup, hardly causing a sticky feeling and providing a dry feeling is provided.
A rod (10) has a number of circumferential grooves (11) dividing it into tablets (12). It is cylindrical with characteristic markings on each tablet.  Pref. the grooves are set at right angles to the long axis, at defined, but not necessarily equal distances, from each other. They have any required shape, possibly triangular, semicircular or rectangular in section, for example. It does not matter whether they have a rough or a smooth surface. On a tablet suitable to make a drink, the required dilution can be visibly identified. Alternatively, the markings can be in the form of a scale, of letters or numerals.
Alzheimer's disease is characterized by progressive impairment of neuronal functions culminating in neuronal loss and dementia. A universal feature of dementia is protein aggregation, a process by which a monomer forms intermediate oligomeric assembly states and filaments that develop into end-stage hallmark lesions. In Alzheimer's disease, this is exemplified by extracellular amyloid-β (Aβ) plaques which have been placed upstream of tau, found in intracellular neurofibrillary tangles and dystrophic neurites. This implies causality that can be modeled as a linear activation cascade. When Aβ load is reduced, for example, in response to an anti-Aβ immunotherapy, cognitive functions improve in plaque-forming mice. They also deteriorate less in clinical trial cohorts although real-world clinical benefits remain to be demonstrated. Given the existence of aged humans with unimpaired cognition despite a high plaque load, the central role of Aβ has been challenged. A counter argument has been that clinical symptoms would eventually develop if these aged individuals were to live long enough. Alternatively, intrinsic mechanisms that protect the brain in the presence of pathology may exist. In fact, Aβ toxicity can be abolished by either reducing or manipulating tau (through which Aβ signals), at least in preclinical models. In addition to manipulating steps in this linear pathocascade model, mechanisms of restoring brain reserve can also counteract Aβ toxicity. Low-intensity ultrasound is a neuromodulatory modality that can improve cognitive functions in Aβ-depositing mice without the need for removing Aβ. Together, this highlights a dissociation of Aβ and cognition, with important implications for therapeutic interventions.
Three hospitals in Shanghai are included: Shanghai Mental Health Center, the Children's Hospital of Fudan University, and Tongji Hospital of Tongji university, and 30 clinicians are recruited in total (10 in each clinical institution). Each clinical institution shall select 2-3 interviewers, who shall participate in interview consistency training. Semi-structured interviews are conducted with the enrolled clinicians using the Clinician Interview Guide. The interview process needs to be recorded, and the interview results need to be qualitatively analyzed.
INTRODUCTION: Wernekinck commissure syndrome (WCS) is an extremely rare midbrain syndrome, which selectively destroys the decussation of the superior cerebellar peduncle and the central tegmental tract, which commonly presents with bilateral cerebellar ataxia, dysarthria, and internuclear ophthalmoplegia. Palatal myoclonus in Wernekinck commissure syndrome is uncommon and often occurs as a late phenomenon due to hypertrophic degeneration of bilateral inferior olivary nuclei.
MATERIAL AND METHOD: A patient with WCS, admitted to our hospital from December 2023, was chosen for this study, and the syndrome's clinical manifestations, imaging features, and etiology were retrospectively analyzed based on the literature. A 68-year-old right-handed East Asian man presented with dizziness, slurred speech, difficulty with swallowing and walking, and rhythmic contractions of the soft palate. He had several risk factors for ischemic cerebrovascular diseases (age, sex, dyslipidemia, hypertension and smoking history). Brain magnetic resonance imaging showed hyperintensity of DWI and hypointensity of ADC at the caudal midbrain which was around the paramedian mesencephalic tegmentum anterior to the aqueduct of midbrain.
RESULTS: He was diagnosed with Wernekinck commissure syndrome (WCS) secondary to caudal paramedian midbrain infarction. He was started on dual antiplatelet therapy (aspirin and clopidogrel) and intensive statin therapy. Blood pressure and glucose were also adjusted. His symptoms improved rapidly, and he walked steadily and speak clearly after 7 days of treatment.
CONCLUSIONS: Palatal myoclonus is known to occur as a late phenomenon due to hypertrophic degeneration of bilateral inferior olivary nuclei. However, Our case suggests that palatal myoclonus can occur in the early stages in WCS.
Control group patients will then be mailed an American Heart Association brochure regarding hypertension and a brief, 5-question, paper-based survey. These patients will be asked to review the brochure, complete the survey, and mail it back to the research team using a self-addressed stamped envelope.
PURPOSE: A method for manufacturing a sample compact is provided to reduce the quality of using the powder and to supply a compact, which can be covered on the face perfectly and to reduce the manufacturing cost by substituting the paper for the plastics as a sample compact body and to maximize the effect of advertising. CONSTITUTION: In the method for manufacturing the sample compact, a sample paper(110), a base board(112) and the sample powder(120) are included. The compact power liquid is manufactured by diluting a solvent made by mixing the existing compact powder, isopropyl alcohol and water. And then the compact powder liquid is printed inside the base board(112) of the sample paper(110). The screen printed sample powder(120) is dried and is adhered in the powder condition. The diluting ratio of isopropyl alcohol and water is 1:4 or 2:1. And the diluting ratio of the compact powder and the solvent is 1:2 or 2:1.
In Arm A, participants with NSCLC (lacking actionable genetic aberrations) will receive lete-cel monotherapy. Participants who subsequently progress by Week 25 will be offered pembrolizumab.
OBJECTIVE: To investigate whether there is an association between the gestational age at the onset of preeclampsia in recurrent cases and the gestational age at the onset of preeclampsia in previous pregnancies.
METHODS: This retrospective nested case-control study was designed to investigate whether gestational age at diagnosis and at delivery in recurrent cases of preeclampsia correlates with gestational age at diagnosis and delivery in the previous cases of preeclampsia in the same individuals. The database of a Ukrainian research network was used to find patients with the diagnosis of preeclampsia between 2019 and 2021. The database was further queried to identify those with a history of preeclampsia in a previous pregnancy. The comparison was made using the Pearson correlation coefficient.
RESULTS: One hundred and three patients who were diagnosed with preeclampsia were identified. Of those, 15 had recurrent preeclampsia, 2 of whom had preeclampsia in 2 previous pregnancies. There was no statistically significant correlation: based on gestational age at delivery R = - 0.28 (P = 0.30; 95% confidence interval (- 0.69 to 0.28) and based on gestational age at the time of diagnosis R = - 0.14 (P = 0.62; - 0.60 to 0.41).
CONCLUSION: Our data do not find an association between the gestational age of recurrent preeclampsia and preeclampsia diagnosed in a previous pregnancy. This supports the idea that there is single pathogenesis for preeclampsia regardless of the gestational age. It suggests that there are variations in the course of preeclampsia that may be determined by the capacity of the compensatory mechanisms.
The utility model relates to an extracting separator. The utility model is composed of a storage tank, a bin, a mixer, a membrane separating circulating pump and a membrane separating component, wherein a powder body inlet of the mixer is communicated with a discharge port on the bottom of the bin through a belt ball valve, an outlet of the mixer is communicated with an upper cover of the storage tank, a liquid inlet of the mixer is communicated with a three-way switching valve, one through port of other two through ports of the three-way switching valve is communicated with a discharge port on the bottom of the storage tank, the other through port is communicated with an inlet of a membrane separating circulating pump, an outlet of the membrane separating circulating pump is communicated with the lower end port of the membrane separating component through another three-way switching valve, and through ports of another three-way switching valve are communicated with a residue discharging pipe. An extract liquid outlet is arranged on the side wall of the membrane separating component, and an upper port of the membrane separating component is communicated with a cover of the storage tank. A solid and liquid dispersive mixing machine with high shear is used for carrying out automatic absorption, and mixing and dispersive extraction to powdery materials. Thereby, automaticity is high, extraction speed is fast and effective components can be completely extracted in five to ten minutes in general situations. The utility model has the advantages of low extraction temperature, high extraction rate, complete removal of impurities, pellucid and transparent extract and no visible impurity.
A contact history construction system includes a plurality of detection devise and a processing device. The plurality of detection devices are used for transmitting a radio wave respectively. The radio wave includes a current time and an identity. The identity corresponds to the detection device transmitting the radio wave. The plurality of detection devices are able to receive the radio wave from each other. The detection device processes the radio wave received into a contact distance according to a signal strength of the radio wave and stores the current time, the identity and the contact distance of the radio wave received in order to construct a contact history. The processing device is coupled to any one of the detection devices and reads the contact history of the detection device coupled thereto.
A dental filling matl. comprises a matrix, produced by mixing mercury and amalgam filings, which contains an additional component to form a structural framework. The latter consists of solids with a hardness greater than that of the set amalgam matrix and with a surface which is capable of amalgamation. They are embedded in such a way that they support each other indirectly in case of compressive stresses, without direct contact between their non-amalgamated cores. This results is a considerable increase in the hardness and mechanical strength of the amalgam filling. The mfg. costs have not been raised unduly.
BACKGROUND: Awake craniotomy (AC) is standard of care for lesions of eloquent brain areas. One important complication during AC is occurrence of intraoperative seizure (IOS), reported to occur among 3.4-20% of the patients. In this study, we report our experience with IOS during AC for resection of gliomas of the language eloquent regions and evaluate the predisposing factors and consequences.
METHODS: Patients who underwent AC for language related regions of the dominant hemisphere from August 2018 to June 2021 were enrolled. The rate of IOS during AC and relationship between predisposing factors and IOS were evaluated.
RESULTS: Sixty-five patients were enrolled (mean age: 44.4±12.5 years). Among 6 patients with IOS (9.2%), only one needed conversion to general anesthesia (GA) due to repeated seizures; while in the remaining 5, AC accomplished successfully despite one seizure attack in the awake phase. Tumor location (especially premotor cortex lesions, P=0.02, uOR:12.0, CI: 1.20-119.91), higher tumor volume (P=0.008, uOR: 1.9, CI: 1.06-1.12) and a functional tumor margin during surgery (P=0.000, uOR: 3.4, CI: 1.47-12.35) were significantly linked with IOS.
CONCLUSIONS: Occurrence of IOS was associated with a longer ICU stay after surgery and worse immediate neurological outcome, but had no impact on the late neurological status. IOS can usually be managed during AC without need to converting to GA. Those with larger tumors, frontal premotor lesions and positive brain mapping are susceptible to IOS. Early neurological deterioration observed after IOS, seems to be transient with no major long-term consequence on the neurological outcome.
New medicaments for percutaneous application contain as active substance the unsaponifiable fraction of colostrum, together with a base for percutaneous application. Used for treating seborrhoea and acne. The medicaments can e.g. take the form of a soap, ointment, cream, milk, lotion, shampoo, spray, aerosol or gel. A typical milk formulation contains 5 g polyethylene glycol 300 mono- and distearates, 2 g polyethylene glycol 1500 mono- and distearates, 5 g paraffin oil, 0.05-5% colostrum unsaponifiable fraction, preservatives and perfume as required, and distilled water q.s. to 100 g.
Benazepril is an effective treatment of hypertension in once-daily doses of 10-80 mg, while hydrochlorothiazide is effective in doses of 12.5-50 mg per day. In clinical trials of benazepril/hydrochlorothiazide combination therapy using benazepril doses of 5-20 mg and hydrochlorothiazide doses of 6.25-25 mg, the antihypertensive effects increased with increasing dose of either component. 

The side effects (see WARNINGS) of benazepril are generally rare and apparently independent of dose; those of hydrochlorothiazide are a mixture of dose-dependent phenomena (primarily hypokalemia) and dose-independent phenomena (e.g., pancreatitis), the former much more common than the latter. Therapy with any combination of benazepril and hydrochlorothiazide will be associated with both sets of dose-independent side effects, but regimens in which benazepril is combined with low doses of hydrochlorothiazide produce minimal effects on serum potassium. In clinical trials of Lotensin HCT, the average change in serum potassium was near zero in subjects who received 5/6.25 mg or 20/12.5 mg, but the average subject who received 10/12.5 mg or 20/25 mg experienced a mild reduction in serum potassium, similar to that experienced by the average subject receiving the same dose of hydrochlorothiazide monotherapy.

To minimize dose-independent side effects, it is usually appropriate to begin combination therapy only after a patient has failed to achieve the desired effect with monotherapy. 

Dose Titration Guided by Clinical Effect: A patient whose blood pressure is not adequately controlled with benazepril monotherapy may be switched to Lotensin HCT 10/12.5 or Lotensin HCT 20/12.5. Further increases of either or both components could depend on clinical response. The hydrochlorothiazide dose should generally not be increased until 2-3 weeks have elapsed. Patients whose blood pressures are adequately controlled with 25 mg of daily hydrochlorothiazide, but who experience significant potassium loss with this regimen, may achieve similar blood-pressure control without electrolyte disturbance if they are switched to Lotensin HCT 5/6.25.

Replacement Therapy: The combination may be substituted for the titrated individual components.

Use in Renal Impairment: Regimens of therapy with Lotensin HCT need not take account of renal function as long as the patient’s creatinine clearance is >30 mL/min/1.73m2 (serum creatinine roughly ≤3 mg/dL or 265 µmol/L). In patients with more severe renal impairment, loop diuretics are preferred to thiazides, so Lotensin HCT is not recommended (see WARNINGS).
The invention belongs to the technical field of biological medical treatment, and relates to a new application of IFN-lambda 2 in Toxoplasma gondii infection. The invention discloses an application of IFN-lambda 2 in preparing a medicament for treating or preventing Toxoplasma gondii infection. The invention also discloses a composition for preventing or treating Toxoplasma gondii infection, which is characterized in that the active ingredient of the composition is IFN-lambda 2. The invention also relates to the use of a composition for the manufacture of a medicament for the prevention or treatment of Toxoplasma gondii infections, wherein the composition comprises IFN-. lambda.2 and one or more pharmaceutically acceptable carriers. The invention provides a new way and a new method for treating Toxoplasma gondii infection, and solves the problem that bad pregnancy caused by Toxoplasma gondii infection cannot be treated in the prior art.
Meditope variants and methods for their use are provided herein. A meditope variant as described herein comprises a peptide having a sequence CQFDLSTRRLKC (SEQ ID NO:1) or CQYNLSSRALKC (SEQ ID NO:2) that has one or more modifications at of least one amino acid residue of the sequence. Multivalent meditope variant tethering entities are also provided. Such entities may include two or more meditopes coupled via a long linker, multivalent scaffold, biotin-streptavidin, or IgG Fc domain. Further, methods of treating, imaging or diagnosing a disease or condition are provided. Such methods may include administering a therapeutically effective amount of a pharmaceutical composition to a subject, the pharmaceutical compound comprising an antibody-meditope complex; a multivalent tethering agent in combination with a monoclonal antibody or functional fragment thereof; or a combination thereof.
Within the field of medical science, there is a great deal of interest in investigating cell death pathways in the hopes of discovering new drugs. Over the past two decades, pharmacological research has focused on necroptosis, a cell death process that has just been discovered. Receptor-interacting protein kinase 1 (RIPK1), an essential regulator in the cell death receptor signalling pathway, has been shown to be involved in the regulation of important events, including necrosis, inflammation, and apoptosis. Therefore, researching necroptosis inhibitors offers novel ways to treat a variety of disorders that are not well-treated by the therapeutic medications now on the market. The research and medicinal potential of RIPK1 inhibitors, a promising class of drugs, are thoroughly examined in this study. The journey from the discovery of Necrostatin-1 (Nec-1) to the recent advancements in RIPK1 inhibitors is marked by significant progress, highlighting the integration of traditional medicinal chemistry approaches with modern technologies like high-throughput screening and DNA-encoded library technology. This review presents a thorough exploration of the development and therapeutic potential of RIPK1 inhibitors, a promising class of compounds. Simultaneously, this review highlights the complex roles of RIPK1 in various pathological conditions and discusses potential inhibitors discovered through diverse pathways, emphasizing their efficacy against multiple disease models, providing significant guidance for the expansion of knowledge about RIPK1 and its inhibitors to develop more selective, potent, and safe therapeutic agents.
BACKGROUND: Cryoballoon ablation for treatment of atrial fibrillation (AF) reduces procedure times, but limited data is available about its impact on electrophysiology (EP) lab efficiency in Central and Eastern Europe (CEE). Using CEE-specific procedure data, the present study modeled cryoballoon ablation procedures on EP lab resource consumption to improve efficiency.
METHODS: A discrete event simulation model was developed to assess EP efficiency with cryoballoon ablation. Model inputs were taken from CEE sites within the Cryo Global Registry, namely Czech Republic, Hungary, Poland, Serbia, and Slovakia. The main endpoints were percentage of days that resulted in overtime and percentage of days with time for one extra simple EP procedure. Use of the 'figure of 8' (Fo8) closure technique to reduce procedure time was also examined.
RESULTS: The mean lab occupancy time across all CEE sites was 133 ± 47 minutes (min: 104 minutes, max:181 minutes). Cryoballoon ablation in the base-case scenario resulted in 14.6% of days with overtime and 64.8% of days with time for an extra simple EP procedure. Use of the Fo8 closure technique enhanced these values to 5.5% and 85.3%, respectively. Model endpoints were most sensitive to changes in lab occupancy times and overtime start time.
CONCLUSIONS: In this CEE-specific analysis of EP lab efficiency it was found that 3 cryoballoon ablation procedures could be performed in 1 lab day, leaving time for a 4th simple EP procedure on most days. As such, use cryoballoon ablation for PVI is an effective way to improve EP lab efficiency.
Ciprofloxacin Otic Solution is a clear, colorless, sterile, preservative-free solution. Ciprofloxacin Otic Solution is supplied as a 0.2% otic solution in a low-density polyethylene (LDPE) single use container. Each single use container delivers 0.25 mL of solution equivalent to 0.5 mg of ciprofloxacin; 14 single use containers are packaged in a foil overwrap pouch in a carton (NDC 42195-550-14).

Store at 15ºC to 25ºC (59ºF to 77ºF). Discard used containers. Store unused containers in pouch to protect from light.